Fenofibrate in Type 2 Diabetes

• Status: Completed
• Trial end date: 2020-03-04
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of South Carolina
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• Type 2 diabetes of at least one year's duration; stable glycemic control (no more than 1.0% change in HbA1c in the previous six months, but no limit on HbA1c)

• Triglycerides >150 mg/dL (in the previous six months)

Exclusion Criteria:

• Previous use of Fenofibrate or other fibrates

• Pregnancy

• Active malignancy

• Recent cardiac event or congestive heart failure

• Active liver disease

• Significant renal impairment (serum creatinine > 2mg/dl)